Market Blog Trending

Further downside for Spark Therapeutics?

Yesterday, Spark Therapeutics, Inc (NASDAQ:ONCE) saw a 35% decline. This was due to an increased negative sentiment for the stock. At the American Society of Hematology’s (ASH) annual meeting, ONCE presented rather disappointing data on their trials of their experimental drug to treat Hemophilia-A. Spark’s data showed that though its therapy reduced bleeding, the drug showed smaller increases in levels a clotting protein that patients with hemophilia are missing, as
Market Blog

Spark Therapeutics and Twilio may have bearish sentiments today

ONCE– Spark Therapeutics is engaged in developing products based on gene therapy. ONCE – Spark Therapeutics Fundamentals Previously closed at 63.87 Day's high 60.48 Day's low 58.84 P/E ratio ­ -19.81   Analysts opinion The average target price for the stock is $51. Many analysts have recently issued reports for the company. Jefferies Group reissued a “hold” rating. Cowen and Company reissued a “buy” rating. Hedge funds have also made